In vitro pharmacokinetics/ pharmacodynamics evaluation of fosfomycin combined with amikacin or colistin against KPC2-producing Klebsiella pneumonia

Frontiers in Cellular and Infection Microbiology

Volumn 7, Issue JUN, 2017, Pages

  Yu, Wei ^a,b   Zhou, Kai ^a   Guo, Lihua ^a   Ji, Jinru ^a   Niu, Tianshui ^a   Xiao, Tingting ^a   Shen, Ping ^a   Xiao, Yonghong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Amikacin; Colistin; Fosfomycin; KPC producing Klebsiella pneumoniae; Pharmacokinetics pharmacodynamics

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; COLISTIN; FOSFOMYCIN;

COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

AMIKACIN; ANTI-BACTERIAL AGENTS; COLISTIN; COMPUTER SIMULATION; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; FOSFOMYCIN; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 85027554991     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2017.00246     Document Type: Article

References (22)

1. Albur, M. S., Noel, A., Bowker, K., and MacGowan, A. (2015). The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int. J. Antimicrob. Agents 46, 560–567. doi: 10.1016/j.ijantimicag.2015.07.019
2. Apisarnthanarak, A., and Mundy, L. M. (2012). Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with highdose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int. J. Antimicrob. Agents 39, 271–272. doi: 10.1016/j.ijantimicag.2011.11.012
3. Centers for Disease Control and Prevention (2013). Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: Centers for Disease Control and Prevention.
4. Clinical and Laboratory Standards Institute (2016). Performance Standards for Antimicrobial Susceptibility Testing. 26th Informational Supplement. Available online at: http://www.clsi.org/ (Accessed January 2016).
5. Craig, W. A., Redington, J., and Ebert, S. C. (1991). Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C), 29–40.
6. Craig, W. A. (1998). Pharmacokinetic/Pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1–10. doi: 10.1086/516284
7. Firsov, A. A., Vostrov, S. N., Shevchenko, A. A., and Cornaglia, G. (1997). Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41, 1281–1287.
8. Garraffo, R., Drugeon, H. B., Dellamonica, P., Bernard, E., and Lapalus, P. (1990). Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob. Agents Chemother. 34, 614–621. doi: 10.1128/AAC.34.4.614
9. Hanberger, H., Edlund, C., Furebring, M., Giske, C. G, Melhus A., Nilsson, L. E., et al. (2013). Rational use of aminoglycosides: review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand. J. Infect. Dis. 45, 161–175. doi: 10.3109/00365548.2012.747694
10. Kanj, S. S., and Kanafani, Z. A. (2011). Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase– producing Enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 86, 250–259. doi: 10.4065/mcp.2010.0674
11. Lahiri, S., Bangaru, V., Kumar, R., et al. (2015). “A novel mechanism of action for the synergistic antibacterial activity of colistin and fosfomycin,” in Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC) Annual Meeting, San Diego, CA., 2015. Slide session 150 (C) (Washington, DC: American Society for Microbiology).
12. Lanao, J. M., Dominguez-Gil, A., Tabernero, J. M., and Corbacho, L. (1981). Influence of the route of administration on the pharmacokinetics of amikacin. Eur. J. Clin. Pharmacol. 19, 367–370. doi: 10.1007/BF00544588
13. Leibovici, L., Vidal, L., and Paul, M. (2009). Aminoglycoside drugs in clinical practice: an evidence-based approach. J. Antimicrob. Chemother. 63, 246–251. doi: 10.1093/jac/dkn469
14. Markou, N., Markantonis, S. L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., et al. (2008). Colistin serum concentrations after intravenous administration in critically Ill Patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30, 143–151. doi: 10.1016/j.clinthera.2008.01.015
15. Michalopoulos, A. S., Karatza, D. C., and Gregorakos, L. (2011). Pharmacokinetic evaluation of colistin sodium. Expert opinion on drug metabolism & toxicology. Expert Opin. Drug Metab. Toxicol. 7, 245–255. doi: 10.1517/17425255.2011.541439
16. Mizuyachi, K., Hara, K., Wakamatsu, A., Nohda, S., and Hirama, T. (2011). Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr. Med. Res. Opin. 27, 2261–2270. doi: 10.1185/03007995.2011.626557
17. NIH (2016). Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated 292 Patients With Gram-Negative and/or Gram-Positive Bacterial Colonization. 293 ClinicalTrials.gov Identifier: NCT02218359. 294 Available online at: https://clinicaltrials.gov/ct2/show/NCT02218359 (Accessed 17 June 2016).
18. Patel, G., Huprikar, S., Factor, S. H., Jenkins, S. G., and Calfee, D. P. (2008). Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29, 1099–1106. doi: 10.1086/592412
19. Rafailidis, P. I., and Falagas, M. E. (2014). Options for treating carbapenem-resistant Enterobacteriaceae. Curr. Opin. Infect. Dis. 27, 479–483. doi: 10.1097/QCO.0000000000000109
20. Sauermann, R., Karch, R., Langenberger, H., Kettenbach, J., Mayer-Helm, B., Petsch, M. et al. (2005). Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob. Agents Chemother. 49, 4448–4454. doi: 10.1128/AAC.49.11.4448-4454.2005
21. Sime, F. B., Johnson, A., Whalley, S., Santoyo-Castelazo, A., Montgomery, A. B., Walters, K. A., et al. (2016). Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy. Antimicrob. Agents Chemother. 61:e01763-16. doi: 10.1128/AAC.01763-16
22. Sirijatuphat, R., and Thamlikitkul, V. (2014). Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob. Agents Chemother. 58, 5598–5601. doi: 10.1128/AAC.02435-13